The Breakthrough is Imminent
The stock is no longer just a mere “gamble” on supply bottlenecks, but a bet on the fundamental transformation of healthcare towards a digital direct sales model.
Reading Time: 2 minutes
For a long time, the stock of Hims & Hers was almost exclusively viewed as a speculative vehicle for the hype surrounding weight loss medications (GLP-1). However, recent developments mark a fundamental turning point: the company is emancipating itself from pure dependence on substances like semaglutide and is positioning itself as a leading force in a new era of personalized medicine. The decisive impetus comes from an unexpected source: the announced regulatory turnaround under Robert F. Kennedy Jr. regarding the classification of peptides...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
